FDA Approves Glucovance (Glyburide And Metformin) For Type 2 Diabetes
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Glucovance (Glyburide And Metformin) For Type 2 Diabetes

PRINCETON, NJ -- August 2, 2000 -- Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved Glucovance™ (glyburide and metformin HCl tablets) for use, along with diet and exercise, as initial drug therapy for people with type 2 diabetes.

The drug was also approved as second-line therapy for patients with type 2 diabetes who are currently taking either or a sulfonylurea and a regimen of diet and exercise, but whose blood sugar levels are inadequately controlled.

Glucovance combines glyburide and glucophage -- the two most widely prescribed oral antidiabetic agents -- in a single pill. These agents work together to improve blood sugar in patients with type 2 diabetes.

"Glucovance represents a new approach to managing type 2 diabetes," said Richard J. Lane, president, Worldwide Medicines Group, Bristol-Myers Squibb. "It is our hope that the introduction of this novel agent could change the treatment paradigm for the more than 15 million patients in the U.S. with this condition."

Glucovance will be available in three dosing strengths, including 1.25 mg/250 mg (glyburide/metformin) tablets, 2.5 mg/500 mg tablets, and 5 mg/500 mg.

Glucovance has been proven safe and effective in clinical trials. In rare cases, Glucovance (or glucophage) may cause lactic acidosis, which can be fatal in up to half of the cases. Lactic acidosis occurs mainly in people whose kidneys are not functioning properly. Patients should not take these drugs if they have kidney problems, if they are 80 or older (unless they have their kidneys tested first), if they are taking medication for heart failure, if they have a history of liver disease or if they drink alcohol excessively. The most common side effects of Glucovance are normally minor ones such as diarrhea, nausea, and upset stomach. Less frequently, symptoms of hypoglycemia (low blood sugar) such as lightheadedness, dizziness, shakiness, or hunger may occur.

Related Link: Bristol-Myers Squibb Company.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities